The University of Zakho to Organize a Seminar on "Updates on Cancer Treatment Approaches"

Start Date: Tuesday, 18 February 2020 - End Date: Sunday, 23 February 2020

The University of Zakho is pleased to inform staff and students of the university that a seminar on a topic of huge significance will be conducted at the university. The seminar will be on "Updates on Cancer Treatment Approaches", presented by Professor Dr. Najim Al-Masoudi-Scientific Consultant for Organic and Medical Chemistry.

Date: February 23, 2020, at 10:30 AM.

Venue: The hall of Chemistry-Faculty of Science.

Biography of the presenter:

Place of birth: Basrah, Iraq

Qualification:: B.Sc., Chemistry, Basrah University, 1968-1972

M.Sc., Organic chemistry, Basrah University, 1974-1976

Ph.D., Organic chemistry, University of Newcatle upon Tyne, UK, 1978-Dec.1980.

Thesis: M.Sc.: Photochemical Cyclization of Some Photoactive Sugar Derivatives

Ph.D.: Chemistry of Some of 5-thio-D-Hexoses

Academic positions: *Demonstrator, Chemistry, Basrah Uni., 1973-1976

*Assis. Lecturer, Chemistry, Basrah Uni., 1976-1978

*Lecturer, Organic chemistry, Basrah Uni., 1981-1981

*Assis. Professor, Organic Chemistry, Basrah Uni.,

1986-1992.

*Full Professor, Organic Chemistry, Basrah Uni., 1992-till now.

*Leader of Assoc. researchers and Professor at Konstanz University, 1994-2006.

*Visiting Professor at Sulaimaniya Uni., College of Medicine, Iraq, via the UNDP program, IRI), 2006-2007.

Professor at Basrah University, College of Science, Basrah Uni., 2008-2019. 2

 

* Honor Professor & consultant of medicinal Chemistry, Konstanz

Scholarships: Alexander von Humboldt Foundation fellow (Germany) at the Lab. of Prof. Dr. Dr. W. Pfleifderer, Konstanz University:

1988-1989; 1990-1991; 1994-1995.

Publications: 185 published papers, reviews and articles in books, & Patens.

Teaching: : *Teaching of organic courses (B.Sc, M.Sc. and Ph.D.):

Mechanism of organic chemistry, Stereochemistry, Organic synthesis, Pericyclic reactions, Natural products, Chemistry of Carbohydrates, Chemistry of nucleic acids, Drug chemistry, Heterocyclic chemistry, Chemistry of amino acids, Pyrimidines.

Scientific activities: * Consultant of Saccor Medical group for AIDS management, London.

*Member of the American group (ONE) for fighting AIDS.

* Member of the American Chem. Soc.

* Member of German Chemical Soc. (GDH)

* Member of the Iraqi National Journal of Chemistry

*Reviewers of several international journals: e.g.:

Nucleosides, Nucleotides & Nucleic acids (USA), J. Org. Chem.(USA), Bioorganic & Med. Chem.(USA), Molecules (Switzerland), Carbohydrate chem. (USA)

Z. Naturforschung (German), Monatshefte (Austria), Heterocycles (Japan)

* Participation of several international and national conferences in the field of AIDS and cancer chemotherapy

Awards: * A distinguished and well-known scientist of Basrah University (2009/2010)

* A personal acknowledgement from the Minister of higher education and scientific research (2012) for our remarkable achievments in AIDS chemotherapy research field.

* Acknowledgements and glories of Babylon, Thi-Qar, Missan, Qadisiya, Baghdad and Basrah Universities for presentation of planary lectures concerning our work in designing and synthesis of anti-AIDS and anti-cancer candidates.

* NISA Award for Outstanding Iraqi Research, 2015 for the best paper in Medical and Biomedical Science (in Steroids).

 

Abstract of the seminar:

 Cancer had been always been the most serious disease in human around the world due to its high morbidity and mortality. Breast and prostate cancers are important global health problem and one of principle causes of deaths in human. Currently, the main therapies for cancer include surgical operation, radiotherapy and chemotherapy. However, seven clinically useful anticancer drugs such as vinblastine, vincristine, campotothecin, topotecan, irinotecan, etoposide and paclitaxel are currently used for treatment of various types of cancer. Lysyl Oxidase (LOX) is a targetable secreted molecule involved in breast cancer metastasis (MBC), and arylated derivatives of 3-aminopropanennitrile.HCl (BNPA) are the most potent agents against MBC. Recently, poly(ADP-ribose) polymerase (PARP) inhibitors have been considered as the new successful pathway for cancer treatment. Olaparib 1 is one of these inhibitors, prepared by Jackcon and described for treatment of MBC. Further, aromatase inhibitors like Anastrozol 2 and letrozole 3 have been approved as potent metastatic anti-breast cancer (anti-MBC) drugs.

Prostate cancer (PC-3, and LACaP-Al cell lines) is the second malignancy amongst male worlwide. We have have prepared recently a series of potential steroids bearing various heterocycle scaffolds, and one of these analogues 4 exhibited a significant inhibition for prostate cancer cell lines (PC-3 and LACaP-Al), using MTT assay. The synthesis of such steroid has therefore recieved much attention for further kinetic and molecular docking study, which led to be a promising antiproliferative agent .

Furthermore, have synthesized recently a new analogue, namely Artrozol (5) as a novel analogue for the anti-metastatic breast cancer (MBC) Letrozol (3) via Suzuki cross-coupling reaction. The new analogue 5 exhibited a significant anticancer activity against MCF-7 cell lines of MBC with IC50 of 170 nM, meanwhile the molecular docking study of the new compound with PDB 3eqm revealed a pi-pi interactions of its two phenyl groups with the residue of amino acid His480. In addition, a pi-triazole residue interaction with Fe+2 of porphyrin was observed .

For more information on the biography and abstract of the presenter, click on the following links:

Abstract

Biography